[go: up one dir, main page]

ECSP18008488A - Moléculas de fusión - Google Patents

Moléculas de fusión

Info

Publication number
ECSP18008488A
ECSP18008488A ECIEPI20188488A ECPI201808488A ECSP18008488A EC SP18008488 A ECSP18008488 A EC SP18008488A EC IEPI20188488 A ECIEPI20188488 A EC IEPI20188488A EC PI201808488 A ECPI201808488 A EC PI201808488A EC SP18008488 A ECSP18008488 A EC SP18008488A
Authority
EC
Ecuador
Prior art keywords
fusion molecules
present
relates
aeruginosa
well
Prior art date
Application number
ECIEPI20188488A
Other languages
English (en)
Inventor
Kristian Jensen
Christian Lange
Carsten Corvey
Heike Stump
Marlon Hinner
Dorothea Rat
Astrid Rey
Jochen Kruip
Michael Mourez
Thomas Stuedemann
Hans-Falk Rasser
Laurent Fraisse
Bernhard Calandra
Juergen Schaefer
Alexander Wiedenmann
Christine Rothe
Andrea Allersdorfer
Ingo Focken
Martin Hülsmeyer
Bradley Lunde
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of ECSP18008488A publication Critical patent/ECSP18008488A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a moléculas de fusión que tienen especificidad de unión para pioverdina tipo I, II y III y pioquelina y pueden usarse en varias aplicaciones, incluyendo aplicaciones de diagnóstico y/o terapéuticas, por ejemplo, para inhibir o reducir el crecimiento de P. aeruginosa y/o para prevenir o tratar una infección por biopelícula de P. aeruginosa así como enfermedades o trastornos asociados con una infección por biopelícula de P. aeruginosa. La presente invención también se refiere a métodos para producir las moléculas de fusión descritas en la presente memoria así como a composiciones y kits que comprenden dichas moléculas de fusión. La presente invención se refiere además a moléculas de ácido nucleico que codifican las moléculas de fusión descritas en la presente memoria.
ECIEPI20188488A 2015-07-07 2018-02-06 Moléculas de fusión ECSP18008488A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306106.4A EP3115371A1 (en) 2015-07-07 2015-07-07 Fusion molecules

Publications (1)

Publication Number Publication Date
ECSP18008488A true ECSP18008488A (es) 2018-04-30

Family

ID=53719726

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20188488A ECSP18008488A (es) 2015-07-07 2018-02-06 Moléculas de fusión

Country Status (26)

Country Link
US (2) US10316071B2 (es)
EP (2) EP3115371A1 (es)
JP (1) JP2018524003A (es)
KR (1) KR20180026755A (es)
CN (1) CN107849106A (es)
AR (1) AR105257A1 (es)
AU (1) AU2016289839A1 (es)
BR (1) BR112018000155A2 (es)
CA (1) CA2991298A1 (es)
CL (1) CL2018000015A1 (es)
CO (1) CO2018001188A2 (es)
CR (1) CR20180079A (es)
DO (1) DOP2018000001A (es)
EA (1) EA201890234A1 (es)
EC (1) ECSP18008488A (es)
HK (1) HK1249110A1 (es)
IL (1) IL256694A (es)
MA (1) MA42006A1 (es)
MX (1) MX2018000206A (es)
PE (1) PE20180490A1 (es)
PH (1) PH12018500058A1 (es)
TN (1) TN2017000547A1 (es)
TW (1) TW201716435A (es)
UY (1) UY36772A (es)
WO (1) WO2017005763A1 (es)
ZA (1) ZA201708754B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3259282A1 (en) 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
EP3115371A1 (en) 2015-07-07 2017-01-11 Sanofi Fusion molecules
CN113939307A (zh) * 2019-03-29 2022-01-14 皮里斯制药有限公司 脂质运载蛋白突变蛋白的吸入施用
CN111848734B (zh) * 2020-06-17 2022-04-05 自然资源部第三海洋研究所 一种具有荧光特性的铁载体pvd、制备方法及其用途

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
CA2233725A1 (en) 1998-03-31 1999-09-30 Hemosol Inc. Hemoglobin-hydroxyethyl starch complexes
IL139786A0 (en) 1998-06-08 2002-02-10 Hoffmann La Roche Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
US6403564B1 (en) 1998-10-16 2002-06-11 Schering Corporation Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
JP4469456B2 (ja) 2000-04-19 2010-05-26 第一三共株式会社 緑膿菌鉄獲得系阻害物質のスクリーニング法
CA2440582A1 (en) 2001-03-09 2002-10-03 Dyax Corp. Serum albumin binding moieties
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US7056702B2 (en) 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
EP1814988A2 (en) 2004-11-26 2007-08-08 Pieris AG Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
AU2009264214B2 (en) * 2008-06-24 2013-06-06 Technische Universitaet Muenchen Muteins of hNGAL and related proteins with affinity for a given target
EP2990798B1 (en) 2009-12-07 2019-09-25 Pieris Pharmaceuticals GmbH Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
ES2667066T3 (es) * 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
US10526384B2 (en) * 2012-11-19 2020-01-07 Pieris Pharmaceuticals Gmbh Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereof
CN103074303A (zh) * 2012-12-27 2013-05-01 中国人民解放军第三军医大学 产生抗人ngal特异性单克隆抗体的杂交瘤细胞株及其产生的单克隆抗体与应用
EP3259282A1 (en) * 2015-02-18 2017-12-27 Sanofi Novel proteins specific for pyoverdine and pyochelin
SG11201707872WA (en) 2015-05-18 2017-10-30 Pieris Pharmaceuticals Gmbh Muteins of human lipocalin 2 with affinity for glypican-3 (gpc3)
EP3115371A1 (en) * 2015-07-07 2017-01-11 Sanofi Fusion molecules

Also Published As

Publication number Publication date
ZA201708754B (en) 2018-11-28
IL256694A (en) 2018-03-29
EP3115371A1 (en) 2017-01-11
CO2018001188A2 (es) 2018-05-10
KR20180026755A (ko) 2018-03-13
US20190382455A1 (en) 2019-12-19
PE20180490A1 (es) 2018-03-07
US10947284B2 (en) 2021-03-16
BR112018000155A2 (pt) 2018-09-11
TW201716435A (zh) 2017-05-16
AR105257A1 (es) 2017-09-20
CA2991298A1 (en) 2017-01-12
DOP2018000001A (es) 2018-05-15
MX2018000206A (es) 2018-02-26
US20170029477A1 (en) 2017-02-02
WO2017005763A1 (en) 2017-01-12
US10316071B2 (en) 2019-06-11
CL2018000015A1 (es) 2018-07-13
HK1249110A1 (zh) 2018-10-26
JP2018524003A (ja) 2018-08-30
PH12018500058A1 (en) 2018-07-09
CN107849106A (zh) 2018-03-27
EA201890234A1 (ru) 2018-06-29
AU2016289839A1 (en) 2018-03-01
CR20180079A (es) 2018-04-24
MA42006A1 (fr) 2018-09-28
EP3319986A1 (en) 2018-05-16
TN2017000547A1 (en) 2019-04-12
UY36772A (es) 2017-01-31

Similar Documents

Publication Publication Date Title
CO2017009433A2 (es) Proteínas específicas para pioverdina y pioquelina
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2017002650A1 (es) Compuestos novedosos
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
AR090465A1 (es) Formas solidas de un profarmaco de nucleotidos de tiofosforamidato
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
CL2016002971A1 (es) Combinación.
MX2017009767A (es) Nuevas proteínas específicas para la angiogénesis.
MX360056B (es) Moléculas de unión humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
MX2017009153A (es) Proteinas de fusion de citoquinas.
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
CO2018006667A2 (es) Moléculas de anticuerpo multiespecífico que tienen especificidad para tnf-alfa, il-17a e il-17f
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
MX2016016992A (es) Aptameros especificos de tlr-4 y usos de los mismos.
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX2019009783A (es) Metodo para fabricar una barra que comprende antitranspirante.
ECSP18008488A (es) Moléculas de fusión
BR112017008481A2 (pt) composto antimicótico
MX2015016120A (es) Moleculas de union que se adhieren al factor de complemento c2 humano y usos de los mismos.
CO2017002312A2 (es) Compuestos bicíclicos sustituidos
EA201690191A1 (ru) Фармацевтическая композиция для замедленного высвобождения ланреотида
ECSP15011105A (es) siRNA Y SU USO EN LOS MÉTODOS Y COMPOSICIONES PARA EL TRATAMIENTO Y/O PREVENCIÓN DE TRASTORNOS OCULARES
UY37032A (es) Compuestos de heteroarilbenzimidazol